NASDAQ:RNAZ TransCode Therapeutics (RNAZ) Stock Price, News & Analysis $4.98 -0.11 (-2.16%) Closing price 03:59 PM EasternExtended Trading$5.00 +0.02 (+0.38%) As of 07:31 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesSEC FilingsShort InterestTrendsBuy This Stock About TransCode Therapeutics Stock (NASDAQ:RNAZ) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get TransCode Therapeutics alerts:Sign Up Key Stats Today's Range$4.87▼$5.2050-Day Range$4.98▼$9.1852-Week Range$3.82▼$20.99Volume20,547 shsAverage Volume142,277 shsMarket Capitalization$4.73 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingSell Company Overview TransCode Therapeutics, Inc., a ribonucleic acid (RNA) oncology company, focuses on the development and commercialization of drugs and diagnostics for treating and identifying various cancers. Its lead therapeutic candidate is TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in a range of cancers, including breast, pancreatic, ovarian, colon cancer, glioblastomas, and others. The company is also developing TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1; and TTX-siLIN28B, an siRNA-based inhibitor of RNA-binding protein LIN28B. In addition, the company developing TTX-RIGA, an RNA- based agonist of the retinoic acid-inducible gene I targeting activation of innate immunity in the tumor microenvironment; TTX-CRISPR, a CRISPR/Cas9-based therapy platform for the repair or elimination of cancer-causing genes inside tumor cells; and TTX-mRNA, an mRNA-based platform for the development of cancer vaccines that activate cytotoxic immune responses against tumor cells. TransCode Therapeutics, Inc. was incorporated in 2016 and is based in Boston, Massachusetts. Read More TransCode Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks21st Percentile Overall ScoreRNAZ MarketRank™: TransCode Therapeutics scored higher than 21% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion0.7 / 5Analyst RatingSell Consensus RatingTransCode Therapeutics has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageTransCode Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about TransCode Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of TransCode Therapeutics is -0.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of TransCode Therapeutics is -0.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioTransCode Therapeutics has a P/B Ratio of 0.44. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about TransCode Therapeutics' valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted2.97% of the float of TransCode Therapeutics has been sold short.Short Interest Ratio / Days to CoverTransCode Therapeutics has a short interest ratio ("days to cover") of 1.87, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in TransCode Therapeutics has recently decreased by 22.40%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldTransCode Therapeutics does not currently pay a dividend.Dividend GrowthTransCode Therapeutics does not have a long track record of dividend growth. News and Social Media2.7 / 5News Sentiment0.25 News SentimentTransCode Therapeutics has a news sentiment score of 0.25. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.83 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for TransCode Therapeutics this week, compared to 1 article on an average week.Search InterestOnly 1 people have searched for RNAZ on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat Follows2 people have added TransCode Therapeutics to their MarketBeat watchlist in the last 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, TransCode Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders0.10% of the stock of TransCode Therapeutics is held by insiders.Percentage Held by InstitutionsTransCode Therapeutics has minimal institutional ownership at this time.Read more about TransCode Therapeutics' insider trading history. Receive RNAZ Stock News and Ratings via Email Sign-up to receive the latest news and ratings for TransCode Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. RNAZ Stock News HeadlinesRNAZ: Introducing RNA therapeuticsJune 8 at 1:00 PM | msn.comTransCode Therapeutics to Host R&D Webcast on June 18, 2026June 8 at 8:04 AM | prnewswire.comSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a $1.75 trillion IPO - larger than Saudi Aramco and any tech offering in history. CNBC calls it 'the big market event of 2026.' According to former tech executive and angel investor Jeff Brown, there's a way to claim a stake before the public filing drops, starting with as little as $500.June 9 at 1:00 AM | Brownstone Research (Ad)RNAZ Share News TodayJune 4, 2026 | uk.investing.comEXCLUSIVE: TransCode's RNA Therapeutic Achieves 64% Stable Disease Rate In Colorectal Cancer Phase 1 StudyJune 3, 2026 | finance.yahoo.comTransCode Therapeutics Successfully Completes Phase 1a Clinical Trial, Reports Safety and Stabilization Data for TTX-MC138 in Metastatic CancerJune 3, 2026 | prnewswire.comTransCode Therapeutics, Inc.: TransCode Therapeutics Initiates Phase 2a Clinical Trial with TTX-MC138 in Patients with ctDNA Positive Colorectal CancerMay 28, 2026 | finanznachrichten.deTransCode Therapeutics Initiates Phase 2a Clinical Trial with TTX-MC138 in Patients with ctDNA Positive Colorectal CancerMay 27, 2026 | prnewswire.comSee More Headlines RNAZ Stock Analysis - Frequently Asked Questions How have RNAZ shares performed this year? TransCode Therapeutics' stock was trading at $6.83 on January 1st, 2026. Since then, RNAZ stock has decreased by 27.1% and is now trading at $4.98. How were TransCode Therapeutics' earnings last quarter? TransCode Therapeutics Inc. (NASDAQ:RNAZ) announced its earnings results on Friday, May, 15th. The company reported ($21.28) EPS for the quarter. When did TransCode Therapeutics' stock split? TransCode Therapeutics shares reverse split before market open on Tuesday, January 16th 2024.The 1-40 reverse split was announced on Tuesday, January 16th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, January 16th 2024. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. When did TransCode Therapeutics IPO? TransCode Therapeutics (RNAZ) raised $25 million in an initial public offering on Friday, July 9th 2021. The company issued 6,250,000 shares at a price of $4.00 per share. How do I buy shares of TransCode Therapeutics? Shares of RNAZ stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of TransCode Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that TransCode Therapeutics investors own include Plug Power (PLUG), AMC Entertainment (AMC), Nuwellis (NUWE), ARMOUR Residential REIT (ARR), BIOLASE (BIOL) and Imperial Petroleum (IMPP). Company Calendar Last Earnings5/15/2026Today6/09/2026AGM 20267/02/2026Next Earnings (Estimated)8/18/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (17m+) 1-Year History Jun 25 Sep 25 Dec 25 Mar 26 Jun 26 RNAZ's financial health is in the Red zone, according to TradeSmith. RNAZ has been in this zone for over 17 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:RNAZ CIK1829635 Webwww.transcodetherapeutics.com Phone857-837-3099FaxN/AEmployees9Year FoundedN/AProfitability EPS (Trailing Twelve Months)($50.33) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$34.66 million Net MarginsN/A Pretax MarginN/A Return on Equity-875.35% Return on Assets-50.36% Debt Debt-to-Equity RatioN/A Current Ratio3.11 Quick Ratio3.11 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$11.27 per share Price / Book0.44Miscellaneous Outstanding Shares950,000Free Float949,000Market Cap$4.73 million OptionableNot Optionable Beta1.28 A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for June 2026. Learn which stocks have the most short interest and how to trade them. Click the link to see which companies made the list.Get This Free Report This page (NASDAQ:RNAZ) was last updated on 6/9/2026 by MarketBeat.com Staff. From Our PartnersJune 12: $100 Turns Into $100,000?The SpaceX IPO is scheduled for June 12, and former tech executive Jeff Brown - who identified Bitcoin, Tesla,...Brownstone Research | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredYour book attachedYour Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...Profits Run | SponsoredSpaceX just filed. The clock is ticking.Reuters reports Elon Musk filed secretly. Barron's says it's being finalized behind closed doors. CNBC just re...The Oxford Club | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredSpaceX will mint billionaires. You won't be one of them.By the time a company goes public, 95% of profits have already been made. Insiders bought SpaceX at $20 billio...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding TransCode Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share TransCode Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
